The circuit changes that mediate parkinsonian tremor, while likely differing from those
underlying akinesia and rigidity, are not precisely known. In this study, to identify a specific …

We assessed prospectively clinical and quality of life changes in 9 patients with Parkinson's
disease (PD; H&Y ≥ 3) with severe motor fluctuations and dyskinesia who started …

The diagnosis of Parkinson’s disease (PD) occurs after pathogenesis is advanced and many
substantia nigra (SN) dopamine neurons have already died. Now that therapies to block …

Pallidal deep brain stimulation (DBS) is currently the most effective treatment for advanced,
medically refractory dystonia. However, factors predicting clinical outcome are not well …

GTP cyclohydrolase 1, encoded by the GCH1 gene, is an essential enzyme for dopamine
production in nigrostriatal cells. Loss-of-function mutations in GCH1 result in severe reduction …

Background Pallidal deep brain stimulation (DBS) is the best therapeutic option for patients
with disabling primary generalized dystonia (PGD) that is refractory to medications. However, …

Parkinson's disease (PD) is a progressive neurodegenerative disorder in which the major
pathologic substrate is a loss of dopaminergic neurons from the substantia nigra. Our main …

A range of behaviors presumed to be related to dopaminergic medications have been recently
recognized in Parkinson's disease (PD). We evaluated 50 consecutive cognitively intact …

Thalamic deep brain stimulation is a mainstay treatment for severe and drug-refractory
essential tremor, but postoperative management may be complicated in some patients by a …

Deep brain stimulation of the internal globus pallidus is a highly effective and established
therapy for primary generalized and cervical dystonia, but therapeutic success is compromised …